Literature DB >> 24188818

Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies.

Chiara Lambertini1, Patrizia Barzaghi-Rinaudo, Lisa D'Amato, Stefan Schulz, Paolo Nuciforo, Herbert A Schmid.   

Abstract

INTRODUCTION: The expression and reliable detection of somatostatin receptor subtypes (SSTR1-5) is a prerequisite for the successful use of somatostatin analogs in neuroendocrine tumors (NETs). Two sets of monoclonal antibodies (mAbs) against human SSTR1, 2A, 3 and 5 have recently been developed by two independent laboratories using rabbit and mouse hybridomas. Our aim was to evaluate the usefulness of both sets of mAbs for detection of SSTRs in NET samples as they are routinely collected in clinical practice.
METHODS: Mouse and rabbit mAbs were characterized in SSTR1, 2A, 3 and 5-transfected HEK293 cells and human archival samples of pancreatic tissue and NET. Comparative analysis of mAbs was also conducted by immunostaining of a tissue microarray composed of 75 cores of NET.
RESULTS: Immunohistochemical analysis of HEK293 cells showed that both rabbit and mouse mAbs specifically detect their cognate receptor subtype, with mild cytoplasmic cross-reactivity observed for rabbit mAbs. Both sets of mAbs labeled normal pancreatic islets and showed similar patterns of immunoreactivity in NET controls. Direct comparison of mAb sets using a NET tissue microarray revealed strong correlation between rabbit and mouse mAbs against SSTR1 and 5, and moderate correlation for SSTR3. The rabbit mAb against SSTR2A showed higher affinity for its cognate receptor than the corresponding mouse mAb, resulting in a more reliable detection of this SSTR.
CONCLUSIONS: mAbs from both sets are reliable tools for the detection of SSTR1, 3 and 5, whereas the rabbit mAb against SSTR2A is recommended for use in routine clinical testing due to its superior binding affinity.
© 2013.

Entities:  

Keywords:  Antibody; FFPE; GEP; IHC; NETs; Neuroendocrine tumors; Pituitary; SSTR; Somatostatin; Somatostatin analog; Somatostatin receptor; TMA; formalin-fixed paraffin-embedded; gastroenteropancreatic; immunohistochemical; mAb; monoclonal antibody; neuroendocrine tumors; reverse transcription polymerase chain reaction; rtPCR; somatostatin receptor subtype; tissue microarray

Mesh:

Substances:

Year:  2013        PMID: 24188818     DOI: 10.1016/j.regpep.2013.10.007

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  10 in total

1.  Generation and characterization of a human nanobody against VEGFR-2.

Authors:  Lin Ma; Kai Gu; Cheng-Hai Zhang; Xue-Tao Chen; Yi Jiang; Karsten Melcher; Juan Zhang; Min Wang; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2016-04-25       Impact factor: 6.150

Review 2.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

3.  Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours.

Authors:  Ylberta Kajtazi; Daniel Kaemmerer; Jörg Sänger; Stefan Schulz; Amelie Lupp
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-26       Impact factor: 4.553

4.  Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies.

Authors:  Max Czajkowski; Daniel Kaemmerer; Jörg Sänger; Guido Sauter; Ralph M Wirtz; Stefan Schulz; Amelie Lupp
Journal:  BMC Cancer       Date:  2022-07-07       Impact factor: 4.638

5.  Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer.

Authors:  Claudia Stumpf; Daniel Kaemmerer; Elisa Neubauer; Jörg Sänger; Stefan Schulz; Amelie Lupp
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-03       Impact factor: 4.553

6.  Differential somatostatin, CXCR4 chemokine and endothelin A receptor expression in WHO grade I-IV astrocytic brain tumors.

Authors:  Franziska Lange; Daniel Kaemmerer; Julianne Behnke-Mursch; Wolfgang Brück; Stefan Schulz; Amelie Lupp
Journal:  J Cancer Res Clin Oncol       Date:  2018-04-25       Impact factor: 4.553

7.  Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts.

Authors:  Siham Moatassim-Billah; Camille Duluc; Rémi Samain; Christine Jean; Aurélie Perraud; Emilie Decaup; Stéphanie Cassant-Sourdy; Youssef Bakri; Janick Selves; Herbert Schmid; Yvan Martineau; Muriel Mathonnet; Stéphane Pyronnet; Corinne Bousquet
Journal:  Oncotarget       Date:  2016-07-05

8.  Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets.

Authors:  Daniel Kaemmerer; Robin Schindler; Franziska Mußbach; Uta Dahmen; Annelore Altendorf-Hofmann; Olaf Dirsch; Jörg Sänger; Stefan Schulz; Amelie Lupp
Journal:  BMC Cancer       Date:  2017-12-28       Impact factor: 4.430

9.  Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma).

Authors:  Benxia Yu; Zhongsheng Zhang; Hao Song; Yuchun Chi; Chunling Shi; Miao Xu
Journal:  Med Sci Monit       Date:  2017-04-23

10.  Evaluation of Somatostatin and CXCR4 Receptor Expression in a Large Set of Prostate Cancer Samples Using Tissue Microarrays and Well-Characterized Monoclonal Antibodies.

Authors:  Christoph Werner; Olaf Dirsch; Uta Dahmen; Marc-Oliver Grimm; Stefan Schulz; Amelie Lupp
Journal:  Transl Oncol       Date:  2020-05-24       Impact factor: 4.243

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.